Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Zafgen Inc    ZFGN

ZAFGEN INC

(ZFGN)
  Report  
Delayed Quote. Delayed Nasdaq - 05/24 04:00:00 pm
2.66 USD   +0.76%
05/09ZAFGEN : 1Q Earnings Snapshot
AQ
05/09ZAFGEN : Reports First Quarter 2019 Operating and Financial Results
AQ
05/02Zafgen to Announce First Quarter 2019 Financial Results
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Law Offices of Howard G. Smith Announces Investigation on Behalf of Zafgen, Inc. Investors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/15/2019 | 07:51pm EDT

Law Offices of Howard G. Smith announces an investigation on behalf of Zafgen, Inc. investors (“Zafgen” or the “Company”) (NASDAQ: ZFGN) concerning the Company and its officers’ possible violations of federal securities laws.

On March 11, 2019, Zafgen announced its decision to suspend plans to file an investigational new drug application for ZGN-1258, the Company’s candidate for rare metabolic disorders based on a finding in rodent toxicology studies. According to the Company, data showed degeneration and other anomalies in rat muscle tissue to different degrees in both vehicle and dose arms of the studies.

On this news, shares of Zafgen fell $1.71, or 37% to close at $2.89 on March 12, thereby injuring investors.

If you purchased Zafgen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZAFGEN INC
05/09ZAFGEN : 1Q Earnings Snapshot
AQ
05/09ZAFGEN : Management's Discussion and Analysis of Financial Condition and Results..
AQ
05/09ZAFGEN, INC. : Results of Operations and Financial Condition, Financial Statemen..
AQ
05/09ZAFGEN : Reports First Quarter 2019 Operating and Financial Results
AQ
05/02Zafgen to Announce First Quarter 2019 Financial Results
GL
04/04ZAFGEN, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/04Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
03/27GLANCY PRONGAY & MURRAY LLP : Announces Investigation on Behalf of Zafgen, Inc. ..
BU
03/15Law Offices of Howard G. Smith Announces Investigation on Behalf of Zafgen, I..
BU
03/14ZAFGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
More news
Financials ($)
Sales 2019 2,00 M
EBIT 2019 -56,0 M
Net income 2019 -61,8 M
Finance 2019 95,0 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 2,16x
EV / Sales 2020 27,2x
Capitalization 99,3 M
Chart ZAFGEN INC
Duration : Period :
Zafgen Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAFGEN INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 6,33 $
Spread / Average Target 138%
EPS Revisions
Managers
NameTitle
Jeffrey S. Hatfield Chief Executive Officer & Director
Peter Barrett Chairman
Patricia L. Allen CFO & Principal Accounting Officer
Dennis D. Kim Chief Medical Officer
John L. LaMattina Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ZAFGEN INC-46.26%99
GILEAD SCIENCES6.94%85 054
VERTEX PHARMACEUTICALS3.66%43 994
REGENERON PHARMACEUTICALS-16.32%33 671
GENMAB14.61%11 324
SAREPTA THERAPEUTICS INC10.73%8 961